Detailseite
Projekt Druckansicht

Untersuchung der Infiltration und Tumormikromilieu (TME) Interaktion von anti-Glypican 2 (GPC2) Chimären Antigen Rezeptor (CAR) T-Zellen in vollständig immunkompetenten Mausmodellen des kleinzelligen Bronchialkarzinoms (SCLC)

Antragsteller Dr. Hyatt Balke-Want
Fachliche Zuordnung Hämatologie, Onkologie
Förderung Förderung von 2020 bis 2023
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 439733641
 
Erstellungsjahr 2024

Zusammenfassung der Projektergebnisse

CAR T-cell manufacturing utilizing CRISPR/Cas9 is an exciting avenue that has the potential to increase both the access to CAR T-cells and accelerate translation of novel CAR constructs due to ease of good manufacturing practice (GMP) grade template DNA production. However, the non-viral manufacture of CAR T-cells is associated with challenges resulting from modest insertion rates and low target cell numbers respectively. During my postdoctoral fellowship I have identified a novel insertion strategy to engineer T-cell via CRISPR knock-in (HITI) and optimized the conventional insertion method to enable the manufacture of non-viral CRISPR knock-in CAR T-cells. In addition, I applied CRISPR knock-in CAR T-cells against B7-H3 in small cell lung cancer (SCLC), and here identified that low-antigen SCLC as well as non-neuroendocrine SCLC, which shows an epithelial-to-mesenchymal cell state with high levels of TGFb, can be efficiently addressed with B7-H3 CAR T-cells co-expressing cJUN. Finally, I have provided evidence that the manufacture of non-viral engineered T-cells (cJUN+B7-H3 CAR) with large transgenes (3.6kb) inserted in a targeted manner is feasible at clinical scale.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung